pmv pharmaceuticals, inc., a precision oncology company, discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. its lead product candidate is pc14586, a small molecule that corrects and restores p53 function. the company also develops product candidates for p53 r273h hotspot mutation and other p53 hotspot mutations. pmv pharmaceuticals, inc. was formerly known as pj pharmaceuticals, inc. and changed to in july 2013. the company was founded in 2013 and is headquartered in cranbury, new jersey.
Company profile
Ticker
PMVP
Exchange
Website
CEO
David H. Mack
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
463218129
PMVP stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
29 Feb 24
S-8
Registration of securities for employees
24 Jan 24
8-K
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway
18 Jan 24
8-K
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development
5 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights
9 Nov 23
Latest ownership filings
SC 13G/A
JPMORGAN CHASE & CO
9 Apr 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
Boxer Capital, LLC
14 Feb 24
SC 13G
ArrowMark Colorado Holdings LLC
14 Feb 24
SC 13G/A
Avoro Capital Advisors LLC
14 Feb 24
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BlackRock Inc.
29 Jan 24
SC 13G/A
JPMORGAN CHASE & CO
23 Jan 24
SC 13G/A
STATE STREET CORP
23 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 52.88 mm | 52.88 mm | 52.88 mm | 52.88 mm | 52.88 mm | 52.88 mm |
Cash burn (monthly) | 5.38 mm | 3.98 mm | 6.54 mm | 6.87 mm | 5.22 mm | 4.91 mm |
Cash used (since last report) | 36.89 mm | 27.29 mm | 44.83 mm | 47.04 mm | 35.76 mm | 33.63 mm |
Cash remaining | 15.99 mm | 25.59 mm | 8.05 mm | 5.84 mm | 17.12 mm | 19.25 mm |
Runway (months of cash) | 3.0 | 6.4 | 1.2 | 0.8 | 3.3 | 3.9 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 107 |
Opened positions | 9 |
Closed positions | 10 |
Increased positions | 41 |
Reduced positions | 33 |
13F shares | Current |
---|---|
Total value | 329.19 bn |
Total shares | 58.71 mm |
Total puts | 261.00 k |
Total calls | 615.20 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Orbimed Advisors | 6.56 mm | $40.30 bn |
BLK Blackrock | 4.60 mm | $28.22 bn |
JPM JPMorgan Chase & Co. | 4.03 mm | $24.77 bn |
Boxer Capital | 3.16 mm | $19.43 bn |
Avoro Capital Advisors | 3.00 mm | $18.42 bn |
Euclidean Capital | 2.63 mm | $16.13 bn |
Verition Fund Management | 2.47 mm | $15.14 bn |
RTW Investments | 2.38 mm | $14.59 bn |
Alkeon Capital Management | 2.35 mm | $14.41 bn |
Vanguard | 2.04 mm | $12.54 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Jan 24 | Mack David Henry | Common Stock | Grant | Acquire A | No | No | 0 | 163,890 | 0.00 | 442,460 |
18 Jan 24 | Mack David Henry | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.8 | 519,915 | 935.85 k | 519,915 |
18 Jan 24 | Michael Carulli | Common Stock | Grant | Acquire A | No | No | 0 | 82,220 | 0.00 | 91,286 |
18 Jan 24 | Michael Carulli | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.8 | 204,630 | 368.33 k | 204,630 |
18 Jan 24 | Deepika Jalota | Common Stock | Grant | Acquire A | No | No | 0 | 95,555 | 0.00 | 125,501 |
18 Jan 24 | Deepika Jalota | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.8 | 225,095 | 405.17 k | 225,095 |
22 Nov 23 | Orbimed Advisors | Common Stock | Sell | Dispose S | Yes | No | 2.23 | 87,786 | 195.76 k | 0 |
News
Jefferies Initiates Coverage On PMV Pharma with Buy Rating, Announces Price Target of $5
12 Apr 24
PMV Pharmaceuticals PYNNACLE Phase I Data Of Rezatapopt In Advanced Ovarian Cancer Featured In Oral Presentation At 2024 SGO Annual Meeting On Women's Cancer
18 Mar 24
HC Wainwright & Co. Reiterates Buy on PMV Pharma, Maintains $5 Price Target
7 Mar 24
Press releases
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
27 Mar 24
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer
18 Mar 24
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
29 Feb 24